|
|
| | (S)-(2-chloro-4-fluoro-5-(7-morpholinoquinazolin-4-yl)phenyl)(6-methoxypyridazin-3-yl)methanol Basic information |
| | (S)-(2-chloro-4-fluoro-5-(7-morpholinoquinazolin-4-yl)phenyl)(6-methoxypyridazin-3-yl)methanol Chemical Properties |
| Melting point | >198°C (dec.) | | Boiling point | 716.0±60.0 °C(Predicted) | | density | 1.405±0.06 g/cm3(Predicted) | | storage temp. | -20°C Freezer | | solubility | DMSO (Slightly, Heated), Methanol (Slightly, Sonicated) | | pka | 11.35±0.20(Predicted) | | form | Solid | | color | Pale Yellow to Light Green | | InChIKey | MOWXJLUYGFNTAL-FKEMPHOKNA-N | | SMILES | [C@H](C1=CC(C2=C3C(=NC=N2)C=C(N2CCOCC2)C=C3)=C(F)C=C1Cl)(C1=NN=C(OC)C=C1)O |&1:0,r| |
| | (S)-(2-chloro-4-fluoro-5-(7-morpholinoquinazolin-4-yl)phenyl)(6-methoxypyridazin-3-yl)methanol Usage And Synthesis |
| Uses | M-3814 is a reagent used in the preparation of serine/threonine protein kinase inhibitors useful for the treatment of cancer. | | in vivo | In combination with IR, Nedisertib shows efficacy in all of the 6 mouse models of human cancer. In all models, a dose of 2 Gy administered daily for 1 week in combination with Nedisertib induces statically significant tumor growth inhibition compare to IR alone. Nedisertib, alone or in combination with IR, does not induce significant weight loss or visual signs of toxicity in the mice in any study[1]. | | IC 50 | DNA-PK: <3 nM (IC50) |
| | (S)-(2-chloro-4-fluoro-5-(7-morpholinoquinazolin-4-yl)phenyl)(6-methoxypyridazin-3-yl)methanol Preparation Products And Raw materials |
|